Diplomat has been fully accredited for specialty pharmacy since 2012.
URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, education and measurement. It offers a wide range of quality benchmarking programs that reflect the latest changes in health care and provide a symbol of excellence for organizations to showcase their validated commitment to quality and accountability.
URAC’s evidence-based measures and standards are developed through inclusive engagement with a broad range of stakeholders committed to improving the quality of health care.
“We are extremely proud to have received reaccreditation as a specialty pharmacy provider for URAC,” said Gary Kadlec, Diplomat’s president. “This demonstrates our continued education and commitment to achieve high clinical service standards of quality and accountability.”
URAC’s accreditation is nationally recognized by state and federal regulators to ensure the highest level of quality is delivered to consumers. URAC accreditation and its programs and standards appear in state legislation, state regulation and federal regulation.
“URAC’s mission to promote continuous improvements in the quality and efficiency of health care management aligns with our mission to support patients in the quality of their care,” said Jennifer Hagerman, Diplomat’s associate vice president of education and quality.
Diplomat also announced the launch of a Rare Disease Center of Excellence (COE) program that will manage a “high-touch” service offering for rare disease patients.
The Rare Disease COE is custom built to serve the unique needs of rare-disease populations, with a team of specialists who establish one-on-one relationships with patients. This COE program offers patients a single point of contact, a direct line to a specialist. High-touch communication lets the care team work closely with patients, caregivers and physicians, breaking down barriers to medication access and adherence.
“To support patients in their therapy, as part of our pharmaceutical care we also have an enhanced nursing component,” said Kadlec. “We recently added an associate director of nursing to our team to focus our high-touch services and drive more nursing care intervention in one-on-one discussions with patients, for care that is truly customized to a patient’s needs.
“We’ve launched new efforts to amplify patient support and leverage our team’s expertise in managing orphan and ultra-orphan therapies,” he added. “Our new model improves efficiencies and helps promote therapy access for patients, expedites new medicinal launches and eases the burden for every patient on that journey.